AVIR (Atea Pharmaceuticals, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by AVIR officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-23 | Bruno Lucidi | Director | M | — | — |
| 2026-06-23 | Jerome M. Adams | Director | M | — | — |
| 2026-06-23 | Howard Berman | Director | A | — | — |
| 2026-06-23 | Bruce Polsky | Director | M | — | — |
| 2026-06-23 | ARTHUR S KIRSCH | Director | A | — | — |
| 2026-06-23 | Polly A. Murphy | Director | M | — | — |
| 2026-06-23 | FRANKLIN M BERGER | Director | M | — | — |
| 2026-06-23 | BARBARA GAYLE DUNCAN | Director | M | — | — |
| 2026-05-21 | Polly A. Murphy | Director | Buy | — | — |
| 2026-05-20 | Polly A. Murphy | Director | Buy | — | — |
| 2026-03-13 | Andrea Corcoran | See Remarks | M | — | — |
| 2026-02-03 | Andrea Corcoran | See Remarks | MIXED | — | — |
| 2026-02-03 | Wayne Foster | EVP, Chief Accounting Officer | MIXED | — | — |
| 2026-02-03 | Jean-Pierre Sommadossi | President, CEO, and Chairman | MIXED | — | — |
| 2026-02-03 | John Vavricka | Chief Commercial Officer | MIXED | — | — |
| 2026-02-03 | Maria Arantxa Horga | Chief Medical Officer | MIXED | — | — |
| 2026-02-03 | Janet MJ Hammond | Chief Development Officer | MIXED | — | — |
| 2025-06-24 | Howard Berman | Director | A | — | — |
| 2025-06-24 | Jerome M. Adams | Director | M | — | — |
| 2025-06-24 | FRANKLIN M BERGER | Director | M | — | — |
| 2025-06-24 | Bruce Polsky | Director | M | — | — |
| 2025-06-24 | Bruno Lucidi | Director | M | — | — |
| 2025-06-24 | Polly A. Murphy | Director | M | — | — |
| 2025-06-24 | Barbara Gayle Duncan | Director | M | — | — |
| 2025-02-24 | Arthur S Kirsch | Director | A | — | — |
| 2025-02-04 | Janet MJ Hammond | Chief Development Officer | MIXED | — | — |
| 2025-02-04 | Andrea Corcoran | See Remarks | MIXED | — | — |
| 2025-02-04 | Jean-Pierre Sommadossi | President, CEO, and Chairman | MIXED | — | — |
| 2025-02-04 | John Vavricka | Chief Commercial Officer | MIXED | — | — |
| 2025-02-04 | Maria Arantxa Horga | Chief Medical Officer | MIXED | — | — |
| 2025-02-04 | Wayne Foster | EVP, Chief Accounting Officer | MIXED | — | — |
| 2025-01-17 | FRANKLIN M BERGER | Director | Buy | — | — |
| 2025-01-17 | FRANKLIN M BERGER | Director | Buy | — | — |
| 2024-12-12 | FRANKLIN M BERGER | Director | Sell | — | — |
| 2024-09-19 | Jean-Pierre Sommadossi | President, CEO, and Chairman | Sell | — | — |
| 2024-06-21 | Polly A. Murphy | Director | A | — | — |
| 2024-06-21 | Barbara Gayle Duncan | Director | A | — | — |
| 2024-06-21 | Bruce Polsky | Director | Sell | — | — |
| 2024-06-21 | Bruno Lucidi | Director | A | — | — |
| 2024-06-21 | FRANKLIN M BERGER | Director | A | — | — |
| 2024-06-21 | Jerome M. Adams | Director | A | — | — |
| 2024-06-18 | Jerome M. Adams | Director | M | — | — |
| 2024-06-18 | Barbara Gayle Duncan | Director | M | — | — |
| 2024-06-18 | Polly A. Murphy | Director | M | — | — |
| 2024-06-18 | Bruno Lucidi | Director | M | — | — |
| 2024-06-18 | Bruce Polsky | Director | M | — | — |
| 2024-06-18 | FRANKLIN M BERGER | Director | M | — | — |
| 2024-06-07 | Jean-Pierre Sommadossi | President, CEO, and Chairman | Sell | — | — |
| 2024-02-02 | Andrea Corcoran | See Remarks | MIXED | — | — |
| 2024-02-02 | Janet MJ Hammond | Chief Development Officer | MIXED | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | President, CEO, and Chairman | 6,439,948 | — |
| — | — | 6,411,355 | — |
| — | Director | 5,365,659 | — |
| — | 10%+ Owner | 1,654,724 | — |
| — | 10%+ Owner | 1,176,862 | — |
| — | See Remarks | 823,576 | — |
| — | Director | 536,097 | — |
| — | Chief Commercial Officer | 176,672 | — |
| — | Director | 142,350 | — |
| — | Director | 133,040 | — |
| — | Chief Development Officer | 127,665 | — |
| — | Director | 124,806 | — |
| — | Chief Medical Officer | 112,159 | — |
| — | Director | 92,350 | — |
| — | Director | 92,350 | — |
| — | EVP, Chief Accounting Officer | 79,329 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the AVIR quote page; the site-wide leaderboard is on the insider transactions hub.